Cardiac Amyloidosis
No Results
No Results
processing….
Cardiac amyloidosis is a clinical disorder caused by extracellular deposition of insoluble fibrils (approximately 7.5-10 nm wide) with beta-pleated sheet configuration. [1] The protein misfolding abnormalities result in amyloid fibrils and may manifest as primary, secondary, or familial amyloidosis. Amyloid deposition can occur in multiple organs (eg, heart, liver, kidney, skin, eyes, lungs, nervous system) resulting in a variety of clinical manifestations. [2] Cardiac involvement is a progressive disorder resulting in early death due to congestive heart failure (CHF) and arrhythmias. Cardiac involvement can occur as part of a systemic disease or as a localized phenomenon. [3, 4]
Educating patients about dietary restrictions and medications is useful. Education about symptoms of heart failure and stroke would be helpful in guiding patients to seek early medical advice.
This article provides an overview of the primary systemic amyloidosis (AL) that predominantly affects the heart. [5]
The characteristic abnormality in amyloidosis is an abnormal folding of a protein, rendering it to be insoluble. [6] These abnormalities may be a result of genetic mutations or excess formation. Various proteins may form amyloid fibrils; light chain amyloidosis (AL) is the most common type of systemic amyloidosis that results from the proliferation of plasma cells in the bone marrow. The plasma cell burden in AL is about 5-10% and is a marker of poor prognosis. [7, 8] Lambda light chains are 3 times more likely involved than kappa chains.
Most cases of AL are associated with a benign monoclonal gammopathy. Only rarely is AL seen in patients with multiple myeloma, lymphoma, or macroglobulinemia. Amyloid deposition in the tissues causes disruption of architecture, induces oxidant stress, and results in organ dysfunction. Multiorgan involvement is common. Cardiac involvement is most common in the AL variety but is also seen in secondary, hereditary, and senile amyloidosis.
Cardiac amyloid deposition is most common in the myocardium but is also seen in the atria, pericardium, endocardium, and vasculature. The myocardium becomes thick (mean weight 500 g) with a rubbery consistency. [9] High-grade infiltration (>50%) of myocardium is most common in the AL variety, and 90% of cases have vascular involvement. [10] Epicardial vessels are typically spared, but microvascular involvement is common, resulting in tissue ischemia and infarction. [11, 12, 13] Resultant myocardial fibrosis adds to the myocardial dysfunction, causing heart failure and cardiac arrhythmias.
The ventricular cavities are typically normal in size, but the ventricles are stiff, which cause restrictive ventricular filling and biatrial enlargement. Pericardial involvement is common and leads to pericardial effusion. [14] Endocardial involvement may result in atrioventricular valve dysfunction. Intracardiac thrombosis is common and seen in about 33% cases in autopsy specimens. [15] The thickening of the left heart valves is common in patients with AL, is associated with advanced age, and increases all-cause mortality. [16] These patients have poor functional class and worse systolic and diastolic function. [16]
Conduction system abnormalities (ie, bundle branch block and atrioventricular block) are frequent in amyloidosis. In a small series, severe sinoatrial node fibrosis was seen in 30% cases. [17]
Primary amyloidosis (AL) is a type of plasma cell dyscrasia and is the most common type involving the heart.
Secondary systemic amyloidosis seen in chronic inflammatory conditions rarely involves the heart. Organ dysfunction is usually reversible with resolution of the underlying inflammatory disorder.
Senile amyloidosis is common in people over 80 years of age and has a better prognosis.
Systemic amyloidosis (AL) is a rare disorder, and it is difficult to estimate the exact incidence due to changing diagnostic criteria. In Olmsted County, Minnesota, only 21 cases were diagnosed from Jan 1950 to Dec 1989. In this first population-based study, the incidence of AL was approximately 8.9 per million person years. [18] In the United States, approximately 2000-2500 cases of AL are diagnosed annually. [19]
Amyloidosis is reported as a cause of death in 1 in 1000 of the British population.
AL is uncommon in non-white individuals and persons younger than 40 years, [20] and it affects men and women equally. Senile amyloidosis, in which wild-type transthyretin (TTR) accumulates in tissue and leads to the development of cardiac dysfunction, [21] is 3 times more common in elderly black patients compared to white patients (8.2% vs 2.7%, respectively). [22] Hereditary cardiac amyloidosis resulting from a mutation in TTR (>100 TTR variants [23] ) is more common in black individuals than white persons; 23% of the patients have this variant. [24]
AL type is usually seen in persons older than age 50 years. Although unusual, it can occur as early as the third decade of life. Late onset amyloidosis (senile) is seen in elderly patients and has a better prognosis than primary amyloidosis.
In general, cardiac involvement is a marker of poor prognosis. [25, 26] Therefore, any clinical, laboratory or imaging abnormality that suggests increased cardiac involvement will be indicative of a worse prognosis. No consensus has been reached about a single most important prognostic factor. The factors associated with a poor prognosis include the following:
Syncope
Complex arrhythmia
Degree of left ventricular (LV) hypertrophy (More = worse prognosis)
Low LV ejection fraction (LVEF)
Restrictive hemodynamic
Right ventricular dilatation
Pulmonary hypertension
Low voltage on electrocardiography (ECG)
High brain natriuretic peptide (BNP) levels
High troponin levels
T1 kinetics on gadolinium-enhanced magnetic resonance imaging (MRI) (to demonstrate extent of myocardial involvement)
Amyloidosis has a poor prognosis, and the median survival without treatment is only 13 months. Cardiac involvement has the worst prognosis and results in death in about 6 months after onset of congestive heart failure. Only 5% of the patients with primary amyloidosis survive beyond 10 years. [27] Among 82 patients with cardiac amyloidosis, New York Heart Association (NYHA) class and right ventricular systolic dysfunction (tricuspid annular plane systolic excursion [TAPSE] < 14 mm) independently predicted major adverse cardiac events. [28]
Complications include the following:
Atrial fibrillation
Congestive heart failure
Embolism and stroke
Ventricular arrhythmias
Heart block requiring pacemaker implantation
Pericardial tamponade
Death
Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med. 2004 Feb. 255(2):159-78. [Medline].
Cohen AS. Amyloidosis. N Engl J Med. 1967 Sep 7. 277(10):522-30 contd. [Medline].
Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007 Nov 27. 50(22):2101-10. [Medline].
Desai HV, Aronow WS, Peterson SJ, Frishman WH. Cardiac amyloidosis: approaches to diagnosis and management. Cardiol Rev. 2010 Jan-Feb. 18(1):1-11. [Medline].
Sher T, Gertz MA. Recent advances in the diagnosis and management of cardiac amyloidosis. Future Cardiol. 2014 Jan. 10(1):131-46. [Medline].
Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003 Aug 7. 349(6):583-96. [Medline].
Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997 Sep 25. 337(13):898-909. [Medline].
Perfetti V, Colli Vignarelli M, Anesi E, et al. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica. 1999 Mar. 84(3):218-21. [Medline].
Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol. 1983 Jul. 52(1):137-46. [Medline].
Smith TJ, Kyle RA, Lie JT. Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc. 1984 Aug. 59(8):547-55. [Medline].
Arbustini E, Merlini G, Gavazzi A, et al. Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients. Am Heart J. 1995 Sep. 130(3 pt 1):528-36. [Medline].
Smith RR, Hutchins GM. Ischemic heart disease secondary to amyloidosis of intramyocardial arteries. Am J Cardiol. 1979 Sep. 44(3):413-7. [Medline].
Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med. 2000 Aug 15. 109(3):181-8. [Medline].
Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005 Sep 27. 112(13):2047-60. [Medline].
Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007 Nov 20. 116(21):2420-6. [Medline].
Mohty D, Pradel S, Magne J, et al. Prevalence and prognostic impact of left-sided valve thickening in systemic light-chain amyloidosis. Clin Res Cardiol. 2017 May. 106(5):331-40. [Medline].
Ridolfi RL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients. Am J Med. 1977 May. 62(5):677-86. [Medline].
Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992 Apr 1. 79(7):1817-22. [Medline].
Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North Am. 1999 Dec. 13(6):1211-33, ix. [Medline].
Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998 Feb. 91(2):141-57. [Medline].
Usuku H, Obayashi K, Shono M, et al. Usefulness of plasma B-type natriuretic peptide as a prognostic marker of cardiac function in senile systemic amyloidosis and in familial amyloidotic polyneuropathy. Amyloid. 2013 Dec. 20(4):251-5. [Medline].
Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997 Feb 13. 336(7):466-73. [Medline].
Arruda-Olson AM, Zeldenrust SR, Dispenzieri A, et al. Genotype, echocardiography, and survival in familial transthyretin amyloidosis. Amyloid. 2013 Dec. 20(4):263-8. [Medline].
Buck FS, Koss MN, Sherrod AE, Wu A, Takahashi M. Ethnic distribution of amyloidosis: an autopsy study. Mod Pathol. 1989 Jul. 2(4):372-7. [Medline].
Takashio S, Izumiya Y, Jinnin M, et al. Diagnostic and prognostic value of subcutaneous tissue biopsy in patients with cardiac amyloidosis. Am J Cardiol. 2012 Nov 15. 110(10):1507-11. [Medline].
Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012 Dec 20. 30(36):4541-9. [Medline].
Pennell DJ, Maceira AM. Magnetic resonance imaging in cardiac amyloidosis. JACC Cardiovasc Imaging. 2009 Dec. 2(12):1378-80. [Medline].
Bodez D, Ternacle J, Guellich A, et al. Prognostic value of right ventricular systolic function in cardiac amyloidosis. Amyloid. 2016 Sep. 23(3):158-67. [Medline].
Ritts AJ, Cornell RF, Swiger K, Singh J, Goodman S, Lenihan DJ. Current concepts of cardiac amyloidosis: diagnosis, clinical management, and the need for collaboration. Heart Fail Clin. 2017 Apr. 13(2):409-16. [Medline].
Chamarthi B, Dubrey SW, Cha K, Skinner M, Falk RH. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol. 1997 Nov 1. 80(9):1242-5. [Medline].
Al Suwaidi J, Velianou JL, Gertz MA, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med. 1999 Dec 7. 131(11):838-41. [Medline].
Navarro JF, Rivera M, Ortuno J. Cardiac tamponade as presentation of systemic amyloidosis. Int J Cardiol. 1992 Jul. 36(1):107-8. [Medline].
Mathew V, Olson LJ, Gertz MA, Hayes DL. Symptomatic conduction system disease in cardiac amyloidosis. Am J Cardiol. 1997 Dec 1. 80(11):1491-2. [Medline].
Zubkov AY, Rabinstein AA, Dispenzieri A, Wijdicks EF. Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology. 2007 Sep 11. 69(11):1136-41. [Medline].
Daoud MS, Lust JA, Kyle RA, Pittelkow MR. Monoclonal gammopathies and associated skin disorders. J Am Acad Dermatol. 1999 Apr. 40(4):507-35; quiz 536-8. [Medline].
Burroughs EI, Aronson AE, Duffy JR, Kyle RA. Speech disorders in systemic amyloidosis. Br J Disord Commun. 1991 Aug. 26(2):201-6. [Medline].
Damy T, Deux JF, Moutereau S, et al. Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis. Amyloid. 2013 Dec. 20(4):212-20. [Medline].
Hamer JP, Janssen S, van Rijswijk MH, Lie KI. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J. 1992 May. 13(5):623-7. [Medline].
Nishikawa H, Nishiyama S, Nishimura S, et al. Echocardiographic findings in nine patients with cardiac amyloidosis: their correlation with necropsy findings. J Cardiol. 1988 Mar. 18(1):121-33. [Medline].
Siqueira-Filho AG, Cunha CL, Tajik AJ, Seward JB, Schattenberg TT, Giuliani ER. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation. 1981 Jan. 63(1):188-96. [Medline].
Rahman JE, Helou EF, Gelzer-Bell R, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2004 Feb 4. 43(3):410-5. [Medline].
Bellavia D, Abraham TP, Pellikka PA, et al. Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr. 2007 Oct. 20(10):1194-202. [Medline].
Klein AL, Hatle LK, Taliercio CP, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1990 Nov. 16(5):1135-41. [Medline].
Hongo M, Kono J, Yamada H, et al. Doppler echocardiographic assessments of left ventricular diastolic filling in patients with amyloid heart disease. J Cardiol. 1991. 21(2):391-401. [Medline].
Ha JW, Ommen SR, Tajik AJ, et al. Differentiation of constrictive pericarditis from restrictive cardiomyopathy using mitral annular velocity by tissue Doppler echocardiography. Am J Cardiol. 2004 Aug 1. 94(3):316-9. [Medline].
Schiano-Lomoriello V, Galderisi M, Mele D, et al. Longitudinal strain of left ventricular basal segments and E/e’ ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: an automated function imaging study. Echocardiography. 2016 Sep. 33(9):1335-43. [Medline].
Salinaro F, Meier-Ewert HK, Miller EJ, et al. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017 Sep 1. 18(9):1057-64. [Medline].
Bodez D, Ternacle J, Guellich A, et al. Prognostic value of right ventricular systolic function in cardiac amyloidosis. Amyloid. 2016 Sep. 23(3):158-67. [Medline].
Mohty D, Pibarot P, Dumesnil JG, et al. Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis. Arch Cardiovasc Dis. 2011 Dec. 104(12):611-8. [Medline].
Kwong RY, Heydari B, Abbasi S, et al. Characterization of cardiac amyloidosis by atrial late gadolinium enhancement using contrast-enhanced cardiac magnetic resonance imaging and correlation with left atrial conduit and contractile function. Am J Cardiol. 2015 Aug 15. 116(4):622-9. [Medline].
Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005 Jan 18. 111(2):186-93. [Medline].
Ruberg FL, Appelbaum E, Davidoff R, et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol. 2009 Feb 15. 103(4):544-9. [Medline]. [Full Text].
Austin BA, Tang WH, Rodriguez ER, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging. 2009 Dec. 2(12):1369-77. [Medline].
Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson. 2008 Nov 25. 10:54. [Medline]. [Full Text].
Barison A, Aquaro GD, Pugliese NR, et al. Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging. J Intern Med. 2015 May. 277(5):605-14. [Medline].
Kuetting DL, Homsi R, Sprinkart AM, et al. Quantitative assessment of systolic and diastolic function in patients with LGE negative systemic amyloidosis using CMR. Int J Cardiol. 2017 Apr 1. 232:336-41. [Medline].
Falk RH, Lee VW, Rubinow A, Hood WB Jr, Cohen AS. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol. 1983 Mar 1. 51(5):826-30. [Medline].
Cytawa W, Teodorczyk J, Lass P. Nuclear imaging of amyloidosis. Pol J Radiol. 2014 Jul 24. 79:222-7. [Medline]. [Full Text].
Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens. 2002 Nov. 11(6):649-55. [Medline].
Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005 Feb 15. 95(4):535-7. [Medline].
Dubrey SW, Bilazarian S, LaValley M, Reisinger J, Skinner M, Falk RH. Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am Heart J. 1997 Dec. 134(6):994-1001. [Medline].
Reyners AK, Hazenberg BP, Reitsma WD, Smit AJ. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J. 2002 Jan. 23(2):157-61. [Medline].
Reisinger J, Dubrey SW, Lavalley M, Skinner M, Falk RH. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol. 1997 Oct. 30(4):1046-51. [Medline].
Pellikka PA, Holmes DR Jr, Edwards WD, Nishimura RA, Tajik AJ, Kyle RA. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement. Arch Intern Med. 1988 Mar. 148(3):662-6. [Medline].
Ardehali H, Qasim A, Cappola T, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J. 2004 May. 147(5):919-23. [Medline].
Pomerance A, Slavin G, McWatt J. Experience with the sodium sulphate-Alcian Blue stain for amyloid in cardiac pathology. J Clin Pathol. 1976 Jan. 29(1):22-6. [Medline]. [Full Text].
Kyle RA, Spencer RJ, Dahlin DC. Value of rectal biopsy in the diagnosis of primary systemic amyloidosis. Am J Med Sci. 1966 May. 251(5):501-6. [Medline].
Ansari-Lari MA, Ali SZ. Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test?. Diagn Cytopathol. 2004 Mar. 30(3):178-81. [Medline].
Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015 Jul 30. 126(5):612-5. [Medline].
Sperry BW, Ikram A, Hachamovitch R, et al. Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol. 2016 Jun 28. 67(25):2941-8. [Medline].
Sanchorawala V, Wright DG, Seldin DC, et al. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol. 2002 Jun. 117(4):886-9. [Medline].
Seldin DC, Anderson JJ, Sanchorawala V, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood. 2004 Sep 15. 104(6):1888-93. [Medline].
Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001 Oct. 28(7):637-42. [Medline].
Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004 Apr 15. 103(8):2936-8. [Medline].
Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood. 2005 Apr 1. 105(7):2949-51. [Medline].
Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007 Jan 15. 109(2):457-64. [Medline].
Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives in treatment of AL amyloidosis. Br J Haematol. 2008 Feb. 140(4):365-77. [Medline].
Grogan M, Gertz M, McCurdy A, et al. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World J Transplant. 2016 Jun 24. 6(2):380-8. [Medline].
Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981 Jun. 63(6):1285-8. [Medline].
Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation. 2009 May 12. 119(18):2490-7. [Medline].
Dubrey SW. Amyloid heart disease: a brief review of treatment options. Postgrad Med J. 2012 Dec. 88(1046):700-5. [Medline].
Migrino RQ, Truran S, Gutterman DD, et al. Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol. 2011 Dec. 301(6):H2305-12. [Medline].
Palladini G, Barassi A, Perlini S, et al. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid. 2011 Dec. 18(4):216-21. [Medline].
Ikeda S, Sekijima Y, Tojo K, Koyama J. Diagnostic value of abdominal wall fat pad biopsy in senile systemic amyloidosis. Amyloid. 2011 Dec. 18(4):211-5. [Medline].
Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010 Dec 9. 116(24):5126-9. [Medline].
Tapan U, Seldin DC, Finn KT, et al. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood. 2010 Dec 2. 116(23):5071-2. [Medline].
McCausland KL, Quock TP, Rizio AA, et al. Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis. Br J Haematol. 2018 Nov 22. [Medline].
Manwani R, Hegenbart U, Mahmood S, et al. Deferred autologous stem cell transplantation in systemic AL amyloidosis. Blood Cancer J. 2018 Nov 5. 8(11):101. [Medline]. [Full Text].
Gyanendra K Sharma, MD, FACC, FASE Professor of Medicine and Radiology, Director, Adult Echocardiography Laboratory, Section of Cardiology, Medical College of Georgia at Augusta University
Gyanendra K Sharma, MD, FACC, FASE is a member of the following medical societies: American Association of Cardiologists of Indian Origin, American Association of Physicians of Indian Origin, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Magnetic Resonance, Society of Cardiovascular Computed Tomography
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Terrence X O’Brien, MD, MS, FACC Professor of Medicine/Cardiology, Director, Clinical Cardiovascular Research, Medical University of South Carolina College of Medicine; Director, Echocardiography Laboratory, Veterans Affairs Medical Center of Charleston
Terrence X O’Brien, MD, MS, FACC is a member of the following medical societies: American College of Cardiology, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, South Carolina Medical Association
Disclosure: Nothing to disclose.
Acknowledgments
I like to sincerely thank Chinmaya Sharma for his editorial assistance in the manuscript preparation.
Cardiac Amyloidosis
Research & References of Cardiac Amyloidosis|A&C Accounting And Tax Services
Source
0 Comments